Table 1.

Baseline demographic, disease-related, and psychological characteristics of patients with IBD according to use of antidepressants.

	Prescribed Antidepressants at Baseline (n = 54)	Not prescribed Antidepressants at Baseline (n = 288)	P value ∗
Mean age in years (SD)	47.1 (13.8)	39.6 (16.2)	0.001
Mean duration of follow-up in days (SD) for each endpoint
Glucocorticosteroid prescription or flare of disease activity	648.3 (409)	502.9 (361.8)	0.02
Escalation of medical therapy in response to uncontrolled disease activity	664.0 (399.1)	531.0 (345.3)	0.03
Hospitalisation due to disease activity (%)	841.4 (284.1)	733.2 (252.1)	0.01
Intestinal resection (%)	861.4 (265.6)	770.7 (218.1)	0.02
Female gender (%)	47 (87.0)	158 (54.9)	<0.001
Caucasian ethnicity (%)	51 (96.2)	267 (93.7)	0.47
Married or co-habiting (%)	27 (50.9)	165 (58.3)	0.32
University/postgraduate (%)	16 (29.6)	102 (36.0)	0.37
Mean BMI (SD)	28.0 (6.2)	25.6 (5.3)	0.01
Tobacco user (%)	14 (25.9)	48 (16.8)	0.11
Alcohol user (%)	31 (57.4)	200 (69.9)	0.07
Crohn's disease (%)	20 (37.0)	118 (41.0)	0.59
5-ASA use (%)	27 (50.0)	124 (43.1)	0.35
Immunosuppressant use (%)	16 (29.6)	117 (40.6)	0.13
Biologic use (%)	6 (11.1)	63 (21.9)	0.07
Glucocorticosteroid use (%)	5 (9.3)	26 (9.0)	0.96
HBI/SCCAI <5 (%)	23 (45.1)	159 (58.7)	0.07
HADS anxiety scores at baseline (%)
Normal	16 (29.6)	167 (58.6)
Borderline abnormal	10 (18.5)	10 (18.5)
Abnormal	28 (51.9)	69 (24.2)	<0.001
HADS depression scores at baseline (%)
Normal	29 (53.7)	230 (80.1)
Borderline abnormal	11 (20.4)	35 (12.2)
Abnormal	14 (25.9)	22 (7.7)	<0.001
PHQ-15 somatisation scores at baseline (%)
Mild	0 (0)	50 (18.8)
Low	8 (15.7)	83 (31.2)
Medium	20 (39.2)	78 (29.3)
High	23 (45.1)	55 (20.7)	<0.001

∗Independent samples t-test for continuous data and χ2 for comparison of categorical data.